Press Releases

MGEN $3.51 $ - 0.13 (3.57%)

Press Releases

Search Press Releases
  
Subscribe for Email Alerts
11/1/2018
9:00 AM ET
Press Release

Miragen Therapeutics to Present New Cobomarsen Phase 1 Clinical Trial Data at the 2018 American Society of Hematology Annual Meeting

11/1/2018

BOULDER, Colo., Nov. 01, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted thera...

 Continue Reading
10/29/2018
7:00 AM ET
Press Release

miRagen Therapeutics to Present at two Investor Conferences in November 2018

10/29/2018

BOULDER, Colo., Oct. 29, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted thera...

 Continue Reading
10/24/2018
7:00 AM ET
Press Release

miRagen Therapeutics to Report Third Quarter 2018 Financial Results and Host Conference Call on November 7, 2018

10/24/2018

BOULDER, Colo., Oct. 24, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted thera...

 Continue Reading
10/1/2018
7:00 AM ET
Press Release

miRagen Therapeutics Announces the Presentation of Data From Preclinical Studies Demonstrating the Potential Anti-Fibrotic Effect of Remlarsen in the Cornea at the 2018 OLIGO Meeting in Seattle, WA

10/1/2018

Remlarsen treatment increased corneal re-epithelialization, decreased corneal scar formation, and repressed the expression of several pro-fibrotic genes when compared to placebo treated eyes in a prec...

 Continue Reading
Displaying 1 to 5 (of 65 releases)